Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment.

ABSTRACT:

Background

Prostate cancer (PCa) is one of the most commonly diagnosed cancers. Treatments for PCa with less adverse effects than whole gland interventions, such as focal therapy (FT), often involve a higher risk of PCa recurrence. Combining FT with other treatments could increase the efficacy while maintaining a low side effect profile. This study aims to determine the proportion of residual/recurrent clinically significant PCa following the combination treatment of three months of androgen deprivation therapy (ADT) and FT of the prostate, as well as the safety of this treatment regimen.

Methods

This study will be a single arm phase II trial with a recruitment goal of 57 patients with treatment naïve non-metastatic intermediate risk PCa. Patients will complete the I-PSS, SH

SUBMITTER: Koehler J 

PROVIDER: S-EPMC12707638 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature